GlassScriptPrepare for your visit
Michael John Langworthy
Orthopaedic Surgery · North Dartmouth, MA · NPI 1841301546
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$714,608.43
in general payments reported to CMS, 2019-2025 · $134K in 2025
The $134K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Who reported paying
General payments only, top 6 by amount.
- Ortho Development Corporation $569,694.94
- Pacira Therapeutics, INC. $41,153.80
- Heron Therapeutics, INC. $38,628.38
- Uoc USA INC $32,143.17
- Pacira Pharmaceuticals Incorporated $17,649.32
- Sanofi-Aventis U.S. LLC $11,050.95
Drugs and devices associated with these payments
Balanced Knee System Zynrelef U-Star II Uts, Conformity, U-Mii, U2 Revision Stem, Psa, Ustar, U2 Knee Aponvie Zilretta Ustar II Kerecis Surgiclose Ovation Hip Stem Balanced Knee Revision System Kerecis Graftguide Kerecis Omega3 Marigen
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Michael Langworthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/129388/michael-john-langworthy